Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Bio-Europe SpringBio-Europe Spring
Not Confirmed
Not Confirmed
31 March-01 April, 2026
Nutri Ingredients Summ...Nutri Ingredients Summit
Not Confirmed
Not Confirmed
31 March-01 April, 2026
Not Confirmed
Not Confirmed
01-02 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Bio-Europe Spring
Not Confirmed
Contact SupplierBio-Europe Spring
Bio-Europe SpringBio-Europe Spring
Industry Trade Show
Not Confirmed
31 March-01 April, 2026
Nutri Ingredients Summ...Nutri Ingredients Summit
Industry Trade Show
Not Confirmed
31 March-01 April, 2026
Industry Trade Show
Not Confirmed
01-02 April, 2026
Digital content
NEWS #PharmaBuzz
27 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/27/3264092/0/en/Crescent-Biopharma-Announces-Grants-of-Inducement-Awards.html
06 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/06/3251321/0/en/Crescent-Biopharma-Announces-Grants-of-Inducement-Awards.html
23 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/23/3242526/0/en/Crescent-Biopharma-to-Present-at-March-Investor-Conferences.html
19 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/19/3240981/0/en/Crescent-Biopharma-Announces-Grants-of-Inducement-Awards.html
18 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/18/3240098/0/en/Crescent-Biopharma-Announces-First-Patient-Dosed-in-ASCEND-Phase-1-2-Clinical-Trial-of-CR-001-for-the-Treatment-of-Advanced-Solid-Tumors.html
05 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/05/3232891/0/en/Crescent-Biopharma-to-Present-at-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html
Drugs in Development
Details:
CR-001 is a large molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of neoplasms.
Lead Product(s): CR-001
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2026
Lead Product(s) : CR-001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Details : CR-001 is a large molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2026
Details:
CR-001, an unconjugated antibody targeting PD-1 and VEGF, shows promise in treating advanced solid tumors.
Lead Product(s): CR-001
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Antibody, Unconjugated
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2026
Lead Product(s) : CR-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Sichuan Kelun-Biotech Biopharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Crescent Biopharma Clears INDs for CR-001 PD-1 x VEGF Antibody & CR-003 ITGB6 ADC for Solid Tumors
Details : CR-001, an unconjugated antibody targeting PD-1 and VEGF, shows promise in treating advanced solid tumors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 05, 2026
Details:
SKB105, an antibody-drug conjugate targeting ITGB6, shows promise in treating advanced solid tumors.
Lead Product(s): SKB105
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Antibody-drug Conjugate
Recipient: Sichuan Kelun-Biotech Biopharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2026
Lead Product(s) : SKB105
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Sichuan Kelun-Biotech Biopharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Kelun-Biotech Gets IND Approval for ITGB6-Targeted ADC SKB105 from NMPA
Details : SKB105, an antibody-drug conjugate targeting ITGB6, shows promise in treating advanced solid tumors.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 05, 2026
Details:
In a private placement deal, CR-004, an antibody-drug conjugate, secures funding to advance its development in an undisclosed target area.
Lead Product(s): CR-004,Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody-drug Conjugate
Sponsor: Forbion
Deal Size: $185.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 04, 2025
Lead Product(s) : CR-004,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Forbion
Deal Size : $185.0 million
Deal Type : Private Placement
Crescent Biopharma Announces $185M Private Placement
Details : In a private placement deal, CR-004, an antibody-drug conjugate, secures funding to advance its development in an undisclosed target area.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
December 04, 2025
Details:
Through the merger, the combined company will operate under the name Crescent Biopharma and will advance its pipeline activities, including CR-001, which is being evaluated for the treatment of NSCLC.
Lead Product(s): CR-001
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Crescent Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 16, 2025
Lead Product(s) : CR-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Crescent Biopharma
Deal Size : Undisclosed
Deal Type : Merger
Crescent Biopharma Merges with GlycoMimetics and Raises $200M in Placement
Details : Through the merger, the combined company will operate under the name Crescent Biopharma and will advance its pipeline activities, including CR-001, which is being evaluated for the treatment of NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 16, 2025
Details:
The proceeds from the placement will used to advance the clinical development of CR-001, which is being evaluated for the treatment of Non-Small Cell Lung Cancer.
Lead Product(s): CR-001
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Fairmount
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 16, 2025
Lead Product(s) : CR-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Fairmount
Deal Size : $200.0 million
Deal Type : Private Placement
Crescent Biopharma Merges with GlycoMimetics and Raises $200M in Placement
Details : The proceeds from the placement will used to advance the clinical development of CR-001, which is being evaluated for the treatment of Non-Small Cell Lung Cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 16, 2025
Details:
The combined company will advance Crescent’s portfolio of precision-engineered biologics including its lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody.
Lead Product(s): CR-001
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Crescent Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 29, 2024
Lead Product(s) : CR-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Crescent Biopharma
Deal Size : Undisclosed
Deal Type : Merger
GlycoMimetics Enters into Acquisition Agreement with Crescent Biopharma
Details : The combined company will advance Crescent’s portfolio of precision-engineered biologics including its lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 29, 2024
Details:
GMI-1271 (uproleselan) is a E-selectin inhibitor, which is being evaluated to treat adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older.
Lead Product(s): Uproleselan,Etoposide,Mitoxantrone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: The Division of Cancer Treatment and Diagnosis
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 29, 2024
Lead Product(s) : Uproleselan,Etoposide,Mitoxantrone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : The Division of Cancer Treatment and Diagnosis
Deal Size : Inapplicable
Deal Type : Inapplicable
GlycoMimetics Phase 2/3 Uproleselan Study Fails To Meet Primary Cancer Endpoint
Details : GMI-1271 (uproleselan) is a E-selectin inhibitor, which is being evaluated to treat adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2024
Details:
GMI-1271 (uproleselan) is a first-in-class E-selectin antagonist, which is under phase 3 development for the treatment of of adults with relapsed or refractory acute myeloid leukemia.
Lead Product(s): Uproleselan,Etoposide,Mitoxantrone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2024
Lead Product(s) : Uproleselan,Etoposide,Mitoxantrone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GlycoMimetics Announces Results from Phase 3 of Uproleselan for Relapsed AML Patients
Details : GMI-1271 (uproleselan) is a first-in-class E-selectin antagonist, which is under phase 3 development for the treatment of of adults with relapsed or refractory acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 04, 2024
Details:
GMI-1271 (uproleselan) is an investigational, first-in-class E-selectin antagonist, which is under phase 3 clinical development for adults with relapsed or refractory acute myeloid leukemia.
Lead Product(s): Uproleselan,Etoposide,Mitoxantrone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 06, 2024
Lead Product(s) : Uproleselan,Etoposide,Mitoxantrone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GlycoMimetics Announces Results from Phase 3 Study of Uproleselan in AML
Details : GMI-1271 (uproleselan) is an investigational, first-in-class E-selectin antagonist, which is under phase 3 clinical development for adults with relapsed or refractory acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
